Syfovre is a newly licensed therapy for geographic atrophy (GA), the later, irreversible stage of dry age-related macular degeneration (AMD). AMD is a significant cause of vision loss in older adults, and geographic atrophy is its most severe stage. In this stage, damaged retinal cells create spots that increasingly destroy central vision.
Previously, there were no FDA-approved therapies to retard this loss of vision. Syfovre, approved in 2023, is the first drug that offers a glimmer of hope by retarding the progression of GA through managed immune system control.
A retinal specialist delivers this treatment as an injection into the eye. Clinical trials have shown that it can slow the formation of lesions by up to 22%, enabling patients to preserve their vision despite this challenging disease.
What Is Syfovre Used For?
Syfovre is a prescription drug employed to treat geographic atrophy (GA), a late and advanced form of dry age-related macular degeneration (AMD). It is one of the leading causes of blindness, particularly in older people. Understanding how Syfovre works and for whom it is prescribed can assist patients and caregivers in making educated eye care choices.
To learn more about possible reactions, see the common and rare side effects of SYFOVRE injections.
Learning About Geographic Atrophy and Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a disease that occurs as one gets older and is found explicitly in the macula, the area of the retina used for clear, sharp vision. Dry and wet AMD exist, with dry being more prevalent and developing more gradually but ultimately leading to a condition known as geographic atrophy.
Geographic atrophy is the final stage of dry AMD. In GA, regions of cells within the retina are destroyed and killed, creating patches that gradually get larger over time. This leads to a gradual but permanent loss of central vision.
GA patients will find it difficult to perform simple daily activities such as reading, driving, or identifying faces. As GA advances, their quality of life will be significantly impaired, and therefore, they must receive proper treatment.
How does Syfovre work?
Syfovre has pegcetacoplan as its active pharmaceutical ingredient. An eye doctor administers Syfovre by injection into the affected area. Geographic atrophy results from an overactive immune system component, which causes lesions in the retina. Pegcetacoplan regulates the immune system, particularly by targeting the complement system, which is a collection of proteins that may become overactive in GA.
By slowing this system’s process, Syfovre decreases how rapidly retinal lesions occur. While Syfovre won’t undo existing vision loss, it can prevent vision loss by slowing additional damage to the retina. You need regular injections to keep the medicine effective, and your doctor will determine the most suitable treatment regimen.
If you’re comparing your options, here’s a helpful comparison of SYFOVRE and IZERVAY that outlines how both treatments differ in effect and dosing.
Key Facts about Syfovre
Syfovre is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat geographic atrophy due to dry AMD. It is a brand-name medication and requires a prescription from a retina specialist.
Syfovre is typically administered by injection every 25 to 60 days, depending on the patient’s needs and what the physician recommends. Because the drug is injected into the eye, the treatment is administered in a clinic to make it safe and effective.
Who Can Use Syfovre?
Syfovre injection is for adults diagnosed with geographic atrophy due to dry age-related macular degeneration. It is not for people with other forms of eye disease, nor is it indicated for wet AMD, a distinct type of the disease.
Before you begin treatment, your medical and eye history will be reviewed with your doctor to determine if Syfovre is right for you. If you can use it, your retina doctor will explain the advantages, risks, and what can be expected from treatment.
Syfovre at a Glance
In short, Syfovre is a prescription drug. It is administered to decelerate the progression of geographic atrophy in patients with dry AMD. It accomplishes this by calming an overactive immune response in the retina, which works to maintain vision for as long as possible.
A physician administers the drug and requires frequent treatment to work. Since being licensed by the FDA in 2023, Syfovre has become a beacon of hope for those with difficulty seeing due to this challenging disorder.
Take Charge of Your Vision with Expert Guidance
Syfovre is a significant new therapy for geographic atrophy, a severe, dry type of age-related macular degeneration. By preventing retinal damage, Syfovre enables patients to retain their vision and remain independent for longer.
If you or someone close to you has GA, speak to a retina specialist to see whether Syfovre might be a good option to save your vision.
If you or someone close to you has received a diagnosis of dry AMD or geographic atrophy, seeking expert treatment is very critical. Retina Vitreous Associates of Florida (RVAF) has been a retina care leader for over 50 years.
Their board-certified retina doctors offer cutting-edge treatments, such as Syfovre injections, tailored to each individual. With extensive clinical and surgical retina expertise and access to groundbreaking clinical trials, RVAF offers complete care to protect and preserve your eyesight.
To learn more about Syfovre treatment and schedule an appointment with a retina specialist, visit Retina Vitreous Associates of Florida at rvaf.com. Start safeguarding your eyes and halting geographic atrophy with trusted expert care.